Skip Navigation



NDT Advance Access published online on October 25, 2005
Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfi217
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
21/2/324    most recent
gfi217v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Schrijvers, B. F.
Right arrow Articles by Vriese, A. S. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schrijvers, B. F.
Right arrow Articles by Vriese, A. S. D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2005]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
Received February 8, 2005
Accepted September 20, 2005

Original Articles

A neutralizing VEGF antibody prevents glomerular hypertrophy in a model of obese type 2 diabetes, the Zucker diabetic fatty rat

Bieke F. Schrijvers 1, Allan Flyvbjerg 2, Ronald G. Tilton 3, Norbert H. Lameire 4, and An S. De Vriese 5*

1 Renal Unit, Department of Internal Medicine, Gent University Hospital, Gent; Medical Research Laboratories, Clinical Institute, Aarhus University Hospital, Aarhus, Denmark
2 Medical Research Laboratories, Clinical Institute, Aarhus University Hospital, Aarhus, Denmark
3 Division of Endocrinology, Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX, USA
4 Renal Unit, Department of Internal Medicine, Gent University Hospital, Gent
5 Renal Unit, Department of Internal Medicine, Gent University Hospital, Gent; Renal Unit, Department of Internal Medicine, AZ Sint-Jan AV, Brugge, Belgium

* To whom correspondence should be addressed.
An S. De Vriese, E-mail: an.devriese{at}azbrugge.be



  Abstract

Background. Antagonism of vascular endothelial growth factor (VEGF) has improved the outcome in experimental nephropathies of various origins, including diabetic nephropathy in a type 1 diabetic rat model and a type 2 diabetic mouse model. Neutralizing VEGF antibodies prevented glomerular hypertrophy in these models. We examined the renal effects of VEGF blockade in an obese rat model of type 2 diabetic nephropathy and investigated the mechanism underlying the inhibition of glomerular hypertrophy.

Methods. Twenty female Zucker diabetic fatty (ZDF) rats, fed a high-fat diet and aged 10 weeks, were treated with VEGF antibodies or an irrelevant isotype-matched IgG. Ten heterozygous ( fa/+) littermates served as additional non-diabetic, lean controls. Urinary albumin excretion (UAE) and creatinine clearance (CrCl) were assessed at baseline, and at 3 and 5 weeks. Kidney weight and glomerular volume were determined at the end of the study. Glomerular apoptosis was examined with anti-active caspase-3 immunohistochemistry.

Results. All obese animals had established diabetes, hyperlipidaemia and normal blood pressure, which were not influenced by VEGF antibody treatment. ZDF control rats had increased UAE, CrCl, kidney weights and glomerular volumes compared with non-diabetic, lean control rats. VEGF antibody treatment prevented the glomerular hypertrophy, but did not affect UAE, CrCl and kidney weight. Glomerular anti-active caspase-3 immunostaining was not different between the groups.

Conclusions. Inhibition of VEGF prevented early glomerular hypertrophy in ZDF rats with established diabetes. Increased apoptosis of glomerular endothelial cells does not appear to underly the inhibition of glomerular growth.

Keywords: creatinine clearance; diabetes; glomerular volume; urinary albumin excretion; vascular endothelial growth factor; Zucker diabetic fatty rats.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 EndocrinologyHome page
V. R. Drel, W. Xu, J. Zhang, I. A. Pavlov, H. Shevalye, B. Slusher, and I. G. Obrosova
Poly(Adenosine 5'-Diphosphate-Ribose) Polymerase Inhibition Counteracts Multiple Manifestations of Experimental Type 1 Diabetic Nephropathy
Endocrinology, December 1, 2009; 150(12): 5273 - 5283.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
J. Muller-Deile, K. Worthmann, M. Saleem, I. Tossidou, H. Haller, and M. Schiffer
The balance of autocrine VEGF-A and VEGF-C determines podocyte survival
Am J Physiol Renal Physiol, December 1, 2009; 297(6): F1656 - F1667.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
A. R. Chade, X. Zhu, R. Lavi, J. D. Krier, S. Pislaru, R. D. Simari, C. Napoli, A. Lerman, and L. O. Lerman
Endothelial Progenitor Cells Restore Renal Function in Chronic Experimental Renovascular Disease
Circulation, February 3, 2009; 119(4): 547 - 557.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
M. T. Lindenmeyer, M. Kretzler, A. Boucherot, S. Berra, Y. Yasuda, A. Henger, F. Eichinger, S. Gaiser, H. Schmid, M. P. Rastaldi, et al.
Interstitial Vascular Rarefaction and Reduced VEGF-A Expression in Human Diabetic Nephropathy
J. Am. Soc. Nephrol., June 1, 2007; 18(6): 1765 - 1776.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
M. T. Coughlan, V. Thallas-Bonke, J. Pete, D. M. Long, A. Gasser, D. C. K. Tong, M. Arnstein, S. R. Thorpe, M. E. Cooper, and J. M. Forbes
Combination Therapy with the Advanced Glycation End Product Cross-Link Breaker, Alagebrium, and Angiotensin Converting Enzyme Inhibitors in Diabetes: Synergy or Redundancy?
Endocrinology, February 1, 2007; 148(2): 886 - 895.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.